Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.66 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868275 | 0.91 | PDK2 (0.66) | PDK2P2RX7GRM5GRM1GPR119 | |
| SCHEMBL10095079 | 0.85 | P2RX7 (0.58) | PDK2P2RX7GRM5GRM1GPR119 | |
| SCHEMBL20831661 | 0.83 | PDK2 (0.52) | PDK2P2RX7 | |
| SCHEMBL18446208 | 0.82 | PDK2 (0.67) | PDK2P2RX7 | |
| SCHEMBL29875887 | 0.81 | P2RX3 (0.53) | P2RX3 | |
| SCHEMBL1996747 | 0.80 | ESR2 (0.46) | PDK2GRM5GPR119P2RX3ESR2 | |
| SCHEMBL14659735 | 0.80 | ESR2 (0.46) | PDK2GRM5GPR119P2RX3HPGDS | |
| SCHEMBL21253636 | 0.80 | PDK2 (1.00) | PDK2P2RX7 | |
| SCHEMBL18495296 | 0.80 | PDK2 (1.00) | PDK2P2RX7 | |
| SCHEMBL20818116 | 0.79 | PDK2 (0.48) | PDK2P2RX7GRM5GRM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261185-B2 | Bicyclic heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2022-03-01 | — | — | US | disclosed |
| US-20210002278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-10829489-B2 | Bicyclic heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-10829489-B2 | Bicyclic heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200062756-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20200062756-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-02-27 | — | — | US | disclosed |
| EP-3328857-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-08-14 | — | — | EP | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-8124615-B2 | Diketo substituted pyrrolo[2,3-C]pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124615-B2 | Diketo substituted pyrrolo[2,3-C]pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| WO-2009158394-A1 | DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | PDK1, PDK2, PDK3 | PDK2 2/4885P2RX7 3104/4885GRM5 4044/4885 |
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | PDK2 1663/4885P2RX7 3671/4885GRM5 3501/4885 |
| US-20200062756-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | PDK1, PDK2, PDK3 | PDK2 2/4885P2RX7 3104/4885GRM5 4044/4885 |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | DHFR, DHPS, DCK | PDK2 43/4885P2RX7 3549/4885GRM5 1362/4885 |
| US-10829489-B2 | Bicyclic heterocyclic derivatives | PDK1, PDK2, PDK3 | PDK2 2/4885P2RX7 3104/4885GRM5 4044/4885 |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | DHFR, DHPS, DCK | PDK2 43/4885P2RX7 3549/4885GRM5 1362/4885 |
| US-11261185-B2 | Bicyclic heterocyclic derivatives | PDK1, PDK2, PDK3 | PDK2 2/4885P2RX7 3104/4885GRM5 4044/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | PDK2 1663/4885P2RX7 3671/4885GRM5 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.